A Guide to De-escalation of Combination Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study
Crohn's & Colitis 360 · 10.04.2025 · 7 (2)
DOI: 10.1093/crocol/otaf026 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Crohn's & Colitis 360, online erschienen am 18.04.2025. Verfasst von Adam A Saleh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Advanced combination therapy with biologics and small molecules has seen more widespread implementation for inflammatory bowel disease (IBD). However, there is a paucity of data available to guide the successful de-escalation of combination therapy following the achievement of disease remission. Therefore, we pursued this retrospective study to evaluate our center’s approach to de-escalation of these patients.
Methods
IBD patients undergoing de-escalation of combination biologic therapy from May 2017 to March 2023 with a follow-up visit were included. The need for re-escalation, steroid therapy, and hospitalization at follow-up was compared between the de-escalation method, adherence, patient demographics, disease characteristics, and measures of disease activity.
Results
Fifty IBD patients underwent de-escalation, with a median age of 35.7 years. All 50 patients had a follow-up visit within a median of 168 (111) days. Patients were divided into two groups with 12 (24%) patients requiring re-escalation of therapy and 38 (76%) able to maintain or further de-escalate. Of those that required re-escalation, 3 (25%) required the use of systemic steroids and none required hospitalization for IBD. Non-adherence to the de-escalation plan significantly correlated with the need for re-escalation (P < .001).
Conclusions
Patient adherence and the number of prior failed biologic therapies were identified as potential risk factors for re-escalation. The type of agent being de-escalated (biologic or Janus kinase inhibitors [JAKi] did not correlate with the need for re-escalation).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA.
- Houston Methodist Hospital, Underwood Center for Digestive Diseases, Fondren Inflammatory Bowel Disease Center, Houston, TX, USA.
- Texas A&M College of Engineering Medicine, Houston, TX, USA.
ORCID-Profile: Adam A Saleh, Kerri Glassner, Bincy P Abraham
Zitieren
APA
Saleh, A. A., Waghela, R., Amini, S., Moskow, J., Irani, M., Fan, C., Glassner, K., & Abraham, B. P. (2025). A Guide to De-escalation of Combination Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study. Crohn's & Colitis 360, 7(2). https://doi.org/10.1093/crocol/otaf026
Vancouver
Saleh AA, Waghela R, Amini S, Moskow J, Irani M, Fan C, et al. A Guide to De-escalation of Combination Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study. Crohn's & Colitis 360. 2025;7(2). doi:10.1093/crocol/otaf026
BibTeX
@article{Saleh2025,
author = {Saleh, Adam A and Waghela, Rajdeepsingh and Amini, Shayan and Moskow, Joshua and Irani, Malcom and Fan, Christopher and Glassner, Kerri and Abraham, Bincy P},
title = {A Guide to De-escalation of Combination Therapy in Inflammatory Bowel Disease: A Retrospective Cohort Study},
journal = {Crohn's & Colitis 360},
year = {2025},
volume = {7},
number = {2},
doi = {10.1093/crocol/otaf026}
}
EUVIMED